June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Late-Onset Retinal Macular Degeneration: refining the phenotype
Author Affiliations & Notes
  • Shyamanga Borooah
    MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom
  • Vasileios Papastavrou
    Department of Ophthalmology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
  • Andrew Browning
    Department of Ophthalmology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
  • Baljean Dhillon
    Ophthalmology, University of Edinburgh, Edinburgh, United Kingdom
  • Footnotes
    Commercial Relationships Shyamanga Borooah, None; Vasileios Papastavrou, None; Andrew Browning, None; Baljean Dhillon, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1368. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Shyamanga Borooah, Vasileios Papastavrou, Andrew Browning, Baljean Dhillon; Late-Onset Retinal Macular Degeneration: refining the phenotype. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1368.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Late-onset retinal macular degeneration (L-ORMD) is a rare inherited blinding eye disease. L-ORMD and age-related macular degeneration (AMD) share key clinical characteristics including macular drusenoid spots, choroidal neovascularisation and retinal atrophy. At onset, the diseases are difficult to differentiate. Importantly, a translational pathway now exists for new therapies through human induced pluripotent cell, small animal model, large animal model and identified L-ORMD families. Current phenotyping methods, although informative, do not enable adequate assessment of treatment efficacy. Together these indicate a need to develop better quantifiable clinical markers. This study aims to see if new-generation retinal diagnostic tools can provide clinically useful phenotypic markers using one of the largest L-ORMD patient cohorts.

 
Methods
 

We initially recruited 17 affected cases across two regions in the United Kingdom. Patients had an average age of 63 with 11 male: 6 female ratio. We investigated patients using microperimetry, multifocal ERG, scanning laser ophthalmoscope and HD-OCT, fluorescein angiogram and indo-cyanine green.

 
Results
 

Mean visual acuity for the patients was 0.52(-0.06-1.38) right eye and 0.64(-0.1-1.56)left eye. In early stage 2 disease patients microperimetry was most sensitive from 10 degrees temporal to fovea(Fig 1) and correlated well with reduced multifocal ERG sensitivity. Fluorescein angiogram showed early hyperfluorescent white dots with plaque at macula. ICG showed hypofluorescent mid-peripheral stippled appearance. Hypofluorescent areas at the macula corresponded to white dots seen on colour photograph. HD Oct showed no significant thickening in early stage patient’s macula.(Fig 2)

 
Conclusions
 

We have previously described a staging system for L-ORMD. In intermediate stages, microperimetry, multi focal ERG and autofluorescence help to further characterise the L-ORMD phenotype by highlighting changes to the temporal retina despite little fundus change. These changes appear different from those commonly seen in AMD. This study provides a useful baseline for a long-term cohort study and future planned treatment studies.

 
 
Figure 1 Showing marked temporal microperimetry sensitivity loss despite few fundus changes
 
Figure 1 Showing marked temporal microperimetry sensitivity loss despite few fundus changes
 
 
Figure 2 Colour fundus(A, B), SLO (C, D), FFA(E, F) and ICG(G, H)
 
Figure 2 Colour fundus(A, B), SLO (C, D), FFA(E, F) and ICG(G, H)
 
Keywords: 688 retina • 494 degenerations/dystrophies • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound)  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×